HomeCompareMORF vs EQR

MORF vs EQR: Dividend Comparison 2026

MORF yields 3.51% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $15.4K in total portfolio value
10 years
MORF
MORF
● Live price
3.51%
Share price
$56.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$439.80
Full MORF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MORF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMORFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MORF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MORF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MORF
Annual income on $10K today (after 15% tax)
$298.30/yr
After 10yr DRIP, annual income (after tax)
$373.83/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $2,872.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MORF + EQR for your $10,000?

MORF: 50%EQR: 50%
100% EQR50/50100% MORF
Portfolio after 10yr
$32.8K
Annual income
$2,129.70/yr
Blended yield
6.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MORF
Analyst Ratings
4
Buy
5
Hold
Consensus: Hold
Price Target
$57.00
+0.0% upside vs current
Range: $57.00 — $57.00
Altman Z
60.9
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MORF buys
0
EQR buys
0
No recent congressional trades found for MORF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMORFEQR
Forward yield3.51%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$25.1K$40.5K
Annual income after 10y$439.80$3,819.61
Total dividends collected$4.0K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$57.00$70.35

Year-by-year: MORF vs EQR ($10,000, DRIP)

YearMORF PortfolioMORF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,051$350.94$11,248$547.57$197.00EQR
2$12,187$362.45$12,701$666.53$514.00EQR
3$13,414$373.56$14,405$814.59$991.00EQR
4$14,737$384.26$16,413$999.84$1.7KEQR
5$16,163$394.55$18,795$1,232.92$2.6KEQR
6$17,699$404.42$21,639$1,527.95$3.9KEQR
7$19,352$413.88$25,057$1,903.80$5.7KEQR
8$21,129$422.92$29,197$2,385.87$8.1KEQR
9$23,040$431.56$34,250$3,008.70$11.2KEQR
10$25,092$439.80$40,467$3,819.61$15.4KEQR

MORF vs EQR: Complete Analysis 2026

MORFStock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Full MORF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MORF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MORF vs SCHDMORF vs JEPIMORF vs OMORF vs KOMORF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.